Professor Eugen Leo serves as head of clinical development at Isarna Therapeutics. He is a board-certified Hematologist and Medical Oncologist and targeted therapy development specialist. Before joining the company in July 2012, he served in various positions with growing responsibilities up to the Vice President level within both biotech (Micromet) and large pharmaceutical companies (Johnson&Johnson, Merck-Serono) and then founded his own consulting firm (LeoConsulting) for drug development in 2009. He has over 15 years of experience in Phase I-III clinical development of targeted molecules, (kinase inhibitors, antibodies, antibody derivatives, vaccines and antisense molecules) and has been instrumental for reaching proof-of-concept for the BiTE platform (blinatumomab; Science 321 (5891): 974ff) and development of various other first-in class molecules. He has substantial translational research experience and has spent three years as research fellow at the Sanford-Burnham Institute, La Jolla, CA (USA) working on signal transduction in cancer. He studied medicine at the Universities of Freiburg, Münster, Heidelberg (Germany) and Cincinnati (USA). He is ESMO-certified, holds an M.B.A. from Colorado State University, is an Adjunct Professor in the Department of Hematology and Medical Oncology at Heidelberg University, Germany, teaching medical oncology and currently also serves as Chief Medical Officer of Rigontec GmbH, Munich.